Salivary Duct Carcinoma (SDC)
Salivary duct carcinoma (SDC) is a rare and aggressive type of cancer that originates in the salivary glands. Our company is at the forefront of salivary duct carcinoma drug and therapeutic development services, aiming to provide innovative solutions to help global pharmaceutical companies combat this challenging disease.
Introduction to Salivary Duct Carcinoma (SDC)
Salivary duct carcinoma (SDC) is an uncommon malignancy that arises from the salivary glands, primarily affecting the major salivary glands such as the parotid gland. There are about 2000 to 2500 cases in the United States each year. In the Western world, its incidence is about 3 cases per 100,000 people per year. It is characterized by the aggressive growth of cancer cells within the salivary ducts. Salivary duct carcinoma is known for its high propensity for local invasion, distant metastasis, and poor prognosis.
Pathogenesis of Salivary Duct Carcinoma (SDC)
- Age: Salivary duct carcinoma commonly affects individuals between the ages of 50 and 70, with a higher incidence in males.
- Previous Radiation Exposure: Radiotherapy to the head and neck region, often used to treat other cancers, has been associated with an increased risk of developing salivary duct carcinoma.
- Genetic Alterations: Specific genetic mutations, such as alterations in the HER2 gene, have been implicated in the development of SDC.
Fig. 1 Functional profiling and network analysis of SDC somatic mutations. (Kim Y., et al., 2020)Targets of Salivary Duct Carcinoma (SDC) Therapy
- Androgen Receptor (AR)
Salivary duct carcinoma tumors often express androgen receptors, making them susceptible to hormonal therapies such as androgen deprivation therapy (ADT). - Human Epidermal Growth Factor Receptor 2 (HER2)
HER2 overexpression, observed in a subset of SDC cases, can be targeted using HER2 inhibitors like trastuzumab, leading to improved outcomes.
- BRAF Gene Alterations
Salivary duct carcinoma cases harboring BRAF gene alterations may benefit from targeted therapies, such as BRAF inhibitors. - EGFR and VEGFR Pathways
Inhibition of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) pathways has shown promise in certain salivary duct carcinoma cases.
Therapies of Salivary Duct Carcinoma (SDC)
Chemotherapy
Chemotherapeutic agents, including cyclophosphamide, doxorubicin, cisplatin, gemcitabine, and taxanes (e.g., docetaxel, paclitaxel), have shown varying degrees of efficacy in salivary duct carcinoma cases. Combination therapies have demonstrated objective responses or stable disease in some cases.
Hormonal Therapy
Androgen deprivation therapy (ADT) has shown promise in salivary duct carcinoma cases exhibiting androgen receptor expression. ADT, involving the use of drugs like leuprorelin acetate and bicalutamide, has demonstrated objective responses and improved overall survival rates.
Targeted Therapy
Targeted therapies directed at specific molecular alterations, such as HER2 inhibitors (e.g., trastuzumab), BRAF inhibitors (e.g., vemurafenib), and EGFR/VEGFR inhibitors (e.g., sorafenib, nintedanib), have shown potential in selected salivary duct carcinoma cases.
Our Services
Our company is dedicated to advancing the field of salivary duct carcinoma therapy through cutting-edge diagnostics and therapy development services. We offer a range of services aimed at accelerating the discovery and development of effective therapeutics for salivary duct carcinoma.
Therapy Development Platforms
Animal Models of Salivary Duct Carcinoma (SDC)
We specialize in the development of robust animal models that faithfully recapitulate salivary duct carcinoma characteristics. These models enable the evaluation of novel therapies in a preclinical setting, providing valuable insights into their safety and efficacy.
| Transgenic Model Development | |
| Our company specializes in transgenic model development services for studying salivary duct carcinoma. By introducing specific genetic alterations into animal models, we can mimic the molecular changes observed in human tumors. | |
| Optional Modifier Genes | MYB, NSHL1, Others |
| Xenograft Model Development | |
| Patient-derived xenograft (PDX) models are created by transplanting tumor tissues directly derived from patients into immunodeficient mice. Our company excels in the establishment of patient-derived xenograft (PDX) models specifically designed for salivary duct carcinoma. | |
| Optional Species | Mouse, Rat, Non-human primates, Others |
Furthermore, we offer a wide range of personalized animal models tailored to meet various requirements. If you are interested in our services, please do not hesitate to contact us for further information and details regarding pricing and related services.
References
- Kim Y., et al. "Integrative genomic analysis of salivary duct carcinoma." Scientific reports 10.1 (2020): 14995.
- Nakaguro M., et al. "Salivary duct carcinoma: updates in histology, cytology, molecular biology, and treatment." Cancer cytopathology 128.10 (2020): 693-703.
- Uijen, M. J., et al. "Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review." Cancer Treatment Reviews 89 (2020): 102069.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.